Brimonidine tartrate 0.33% gel for the management of posttreatment erythema induced by laser skin resurfacing - 18/04/17
Doi : 10.1016/j.jaad.2016.10.020
Stephan Alexander Braun, MD a, Ofir Artzi, MD b, Peter Arne Gerber, MD, DALM a, ⁎ 
a Department of Dermatology, Heinrich-Heine University, Düsseldorf, Germany
b Department of Dermatology, Sourasky Medical Center, Tel Aviv, Israel
∗Reprint requests: Peter Arne Gerber, MD, DALM, Department of Dermatology, Heinrich-Heine University, Moorenstr. 5, 40225 Düsseldorf, Germany.Department of DermatologyHeinrich-Heine UniversityMoorenstr. 5Düsseldorf40225Germany
Key words : carbon-dioxide, erbium:yttrium-aluminium-garnet, fractional ablative lasers, management, side effects, therapy
Plan
| Funding sources: None. |
|
| Disclosure: Dr Gerber has served as an investigator, consultant, and speaker for Galderma and Asclepion Laser Technologies; he received honoraria, travel, and research funding from Galderma; and received honoraria for publications from Asclepion Laser Technologies and Lumenis. Drs Braun and Artzi have no conflicts of interest to declare. |
© 2016
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 76 - N° 2
P. e53-e55 - février 2017 Retour au numéro
Article précédent
- Multiple junctional nevi on the buttocks: An indicator of tanning bed use
- Colleen Little, Jenifer Lloyd
- The wingman flap: Bilateral closure of a supra-tip defect of the nose
- Stijn T.P. Kouwenhoven, Marloes S. van Kester, Roel E. Genders
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?